Rick Panicucci

SVP of CMC at QED Therapeutics

Prior to joining BridgeBio, Rick served as VP of Pharmaceutical Development Services at WuXi STA, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Rick was Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis. His responsibilities included analytics, solid state chemistry, and formulation development for all small molecule therapeutics. He also helped develop novel drug delivery technologies for small molecules and large molecules including oligonucleotides. Rick has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. He received a PhD in Chemistry from the University of Toronto and did a post-doctoral fellowship at the University of California, Santa Barbara.


Org chart

No direct reports

Teams


Offices

This person is not in any offices


QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.


Industries

Employees

11-50

Links